More To Go Or Is It Over? – Nuvation Bio Inc (NUVB)

Nuvation Bio Inc (NYSE:NUVB) does about 1.65M shares in volume on a normal day but saw 1671970 shares change hands in Monday trading. The company now has a market cap of 719.69M USD. Its current market price is $2.90, marking an increase of 4.69% compared to the previous close of $2.77. The 52 week high reached by this stock is $4.16 whilst the lowest price level in 52 weeks is $0.95.

Nuvation Bio Inc (NUVB) has a 20-day trading average at $3.09 and the current price is -30.29% off the 52-week high compared with 205.26% distance from its 52-week low. The 50-day simple moving average of the closing price is $3.07 and its 200-day simple moving average is $1.95. If we look at the stock’s price movements over the week, volatility stands at 7.74%, which decreases to 7.08% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 47.00 to suggest the stock is neutral.

The consensus objective for the share price is $6.60, suggesting that the stock has a potential upside of 56.06% over the period.

The company shares received a number of brokerage firm price updates over the past month, with the latest being on March 27, 2024 when Jefferies upgraded the stock to “Buy” and issued a price target of between $1.40 and $10. BTIG Research also upgraded the stock to “Buy” from Neutral on March 26, 2024 at a price target of $5. Jefferies downgraded its price target at $5-$2.

Nuvation Bio Inc (NUVB) stock is up 6.62% over the week and -12.91% over the past month. Its price is 92.05% year-to-date and 67.63% over the past year.

The stock last released its quarterly earnings report for quarter ended 3/31/2024, with the company’s earnings per share (EPS) of -0.09 above consensus estimates by 0.02. The company’s next earnings report forecasts estimating quarterly EPS at -0.06 and -0.28 for whole year.

To reach the target analysts have set, the stock logically needs to grow 56.06 percent from here.

The company has a return on investment of -11.56% and return on equity of -11.15%. The beta has a value of 1.42. Price to book ratio is 1.07.